New drug candidate targeting synaptic resilience well tolerated in Alzheimer’s patients

A small clinical trial suggests that a new type of drug may be safe for people with Alzheimer’s disease and could potentially mitigate some of the brain damage caused by the condition. Findings from the NIA-funded study, published in Nature Medicine, support further research to assess the drug’s long-term safety and effectiveness.